Diabetes Management Apps Market Size & Forecast 2035
The global diabetes management apps market was valued at USD 1.71 billion in 2025 and is forecast to reach USD 15.53 billion by 2035, expanding at a CAGR of 24.7% during 2026–2035. These applications help people record, integrate and interpret glucose, insulin, medication, meals, activity, weight and other information used in day-to-day diabetes care. The market includes consumer subscriptions, licensed clinical software, remote-management platforms and directly attributable digital services, but excludes glucose sensors, meters, insulin pumps and smartphones.
The category is progressing from electronic logbooks to connected decision-support systems. Modern apps can receive continuous glucose monitor data, identify patterns, estimate future glucose direction, connect users with coaches and transmit selected information to clinicians. Commercial value increasingly comes from the intelligence and workflow built around device data rather than basic storage. Platforms that link glucose with food, medication, sleep and activity can create a more useful picture of why readings change and what action may be appropriate.
Growth is also widening beyond intensive insulin management. People with Type 2 diabetes who do not use insulin, users of GLP-1 medicines, women managing diabetes during pregnancy and individuals at risk of metabolic disease are becoming important user groups. Their needs differ from those of pump users, creating demand for modular programs, simpler interfaces and differentiated reimbursement models.
Key Highlights
- Paid subscriptions and licensed programs generated 62% of 2025 revenue, equal to USD 1.06 billion, as employers, health plans, providers and consumers purchased coaching, analytics and connected-care services.
- Digital diabetes management represented 74% of service revenue, or USD 1.27 billion, while diabetes-focused weight and diet management accounted for 26%, valued at USD 0.44 billion.
- Android-based applications captured 56% of the market, equal to USD 0.96 billion, reflecting the operating system’s global smartphone reach and strength across emerging economies.
- Home-based diabetes management held 68% of 2025 revenue, or USD 1.16 billion, because glucose review, medication logs, nutrition guidance and clinician sharing increasingly occur between appointments.
- North America led with 42% of global revenue, equivalent to USD 0.72 billion, supported by digital-health investment, CGM adoption, employer programs and emerging Medicare pathways.
- AI-based predictive analytics represented 32% of application revenue and is becoming a central differentiator through pattern detection, risk prioritization and personalized coaching.
- EHR interoperability, device compatibility and reimbursable clinical workflows are becoming stronger purchasing filters than the number of standalone app features.
Market Definition
Diabetes management apps are mobile or web-based platforms used by patients, caregivers or healthcare teams to support diabetes self-management and clinical monitoring. Included functionality covers glucose visualization, insulin and medicine logging, carbohydrate and meal tracking, activity records, education, coaching, predictive alerts, remote review, pregnancy-specific workflows and connections to compatible glucose meters, CGMs, pumps, smart pens, scales and fitness devices.
Revenue includes consumer subscriptions, enterprise licenses, per-member program fees, provider software, analytics and directly related coaching when delivered through the application. Revenue from diabetes hardware, medicines, general teleconsultation, unrelated weight-loss applications and hospital information systems is excluded. When an app is bundled with a device, only the software or service value attributable to the application is counted.
Market Scope
| Metric | Detail |
| Market value, 2025 | USD 1.71 billion |
| Forecast value, 2035 | USD 15.53 billion |
| CAGR | 24.7% during 2026–2035 |
| Base year | 2025 |
| Historical period | 2023–2024 |
| Forecast period | 2026–2035 |
| Largest subscription model | Paid subscriptions and licensed programs |
| Largest application | Home-based diabetes management |
| Largest region | North America |
| Fastest-growing region | Asia-Pacific |
Market Dynamics
Connected glucose data is replacing manual entry
Manual logging creates missing records, transcription errors and weak retention. Automatic data capture from CGMs, meters, pumps and smart pens reduces user effort and gives clinicians a more continuous history. Applications that normalize data from multiple manufacturers are especially valuable to diabetes clinics because patients rarely use a single hardware ecosystem across the entire population.
Device connectivity also increases technical and commercial complexity. Platforms must maintain integrations across changing device generations, mobile operating systems and regional product configurations. A broad compatibility list can support clinical adoption, but reliability matters more than headline connection count. Failed synchronization undermines trust and can create safety concerns when users assume their records are complete.
Predictive analytics changes diabetes apps from records to interventions
Glucose data is most useful before a preventable problem occurs. Predictive features can identify patterns, estimate future direction and highlight behaviors associated with repeated highs or lows. For people not using insulin, these capabilities can connect food, activity, sleep and medicine adherence with glucose response. For insulin users, prediction must be governed more carefully because recommendations can influence immediate treatment decisions.
AI expands personalization but raises the evidence threshold. Algorithms require diverse training data, defined intended-use claims and ongoing monitoring for performance across age, ethnicity, pregnancy status, medication patterns and comorbidities. Explainable guidance and escalation rules are essential when outputs may affect medical behavior. Companies that secure regulatory authorization or generate peer-reviewed evidence can separate clinically credible functionality from general wellness coaching.
GLP-1 use broadens the cardiometabolic service opportunity
The rise of GLP-1 therapies is bringing weight, nutrition, adherence and body-composition support closer to diabetes management. Applications can help users record doses, side effects, appetite, weight and glucose response while keeping the care team informed. This widens the addressable population and creates cross-selling opportunities for platforms already serving diabetes, hypertension and obesity.
The commercial risk is weak differentiation. Basic dose reminders and meal logs are easy to reproduce, so sustainable value depends on integration with pharmacy, laboratory, device and clinical data. Programs must show that digital support improves persistence, tolerability or outcomes rather than merely adding another app to the user’s phone.
Reimbursement is shifting the market toward accountable care delivery
Consumer subscriptions provide direct revenue, but large-scale adoption increasingly depends on health plans, employers, health systems and public programs. These purchasers expect defined eligibility, engagement reporting, measurable outcomes and secure data exchange. Payment may be linked to enrollment, active use, clinical improvement or total-cost reduction.
The U.S. CMS ACCESS Model illustrates a route for technology-enabled chronic care to participate more directly in Medicare. Such pathways can expand demand but also require credentialing, clinical oversight, documentation and performance measurement. Vendors entering reimbursed care need operational capabilities beyond software development.
Privacy and cybersecurity affect both patient trust and enterprise sales
Diabetes apps handle glucose values, medicine use, pregnancy information, dietary behavior and identifiers that can reveal a person’s health status. Data may flow among devices, app vendors, clinicians, employers, insurers and cloud providers. Users need clear choices about what is collected, how it is used and who can access it.
Enterprise customers assess encryption, identity management, audit trails, incident response and compliance with regional privacy rules. Smaller app developers may struggle with the cost of maintaining these controls. Security maturity is therefore a competitive advantage and a potential source of consolidation.
Engagement remains the central execution risk
Downloading an app does not produce clinical value. Users may stop logging meals, ignore notifications or abandon subscriptions when the burden exceeds the benefit. Apps that demand extensive manual input face the highest attrition. Passive data collection, short actionable messages and personalized goals can reduce friction.
Programs also need human support at the right points. Coaching can improve confidence and sustain behavior change, but labor-intensive models raise delivery cost. Successful providers use software to prioritize members who need intervention while allowing stable users to self-manage.
Market Segmentation
By Subscription Model
Paid subscriptions and licensed programs accounted for 62% of 2025 revenue, equal to USD 1.06 billion. The segment includes direct consumer memberships, employer and health-plan contracts, provider licenses and per-member digital-care programs. Paid models fund advanced analytics, coaching, clinician dashboards and regulated functions. Their growth depends on renewal, verified engagement and evidence that applications improve outcomes or reduce care costs.
Free and freemium applications represented 38%, valued at USD 0.65 billion through advertising, partnerships, limited premium conversion and bundled ecosystem revenue. Free access remains important for user acquisition and underserved populations. However, weak monetization and the cost of security, regulatory maintenance and device integration limit the number of independent free platforms that can sustain clinical-grade services.
By Type of Service
Digital diabetes management led with 74% of market revenue in 2025, or USD 1.27 billion. It covers glucose tracking, insulin and medication support, device integration, education, remote monitoring and clinical decision support. The segment benefits from recurring daily use and direct connection to measurable diabetes outcomes.
Diabetes-focused weight and diet management held 26%, equal to USD 0.44 billion. Demand is rising as Type 2 diabetes care increasingly combines nutrition, physical activity, weight management and GLP-1 support. This segment can grow faster than general logbook functionality because users and purchasers want one cardiometabolic experience instead of separate applications for diabetes and weight.
By Operating System
Android applications represented 56% of 2025 revenue, valued at USD 0.96 billion. Android’s global device share supports reach across Asia-Pacific, Latin America, the Middle East and Africa. Developers must manage a broad range of handset specifications, operating-system versions and manufacturer modifications, making testing and support more complex.
iOS accounted for 44%, equal to USD 0.75 billion. The platform has strong value in North America, Western Europe and Japan, with high consumer spending and close integration with Apple health and wearable services. Many enterprise platforms support both systems, but feature availability and device pairing may differ by country and operating-system version.
By Application
Home-based diabetes management generated 68% of 2025 revenue, or USD 1.16 billion. This includes glucose dashboards, logbooks, medication reminders, food records, coaching and information sharing used outside formal care settings. The segment leads because diabetes requires decisions every day, while clinic visits occur only periodically.
AI-based predictive diabetes analytics accounted for 32%, valued at USD 0.55 billion. The category includes glucose forecasting, risk alerts, pattern recognition, personalized next actions and prioritization for clinical review. It is forecast to gain share as applications move from retrospective charts to anticipatory support, although regulated claims and clinical validation will govern deployment.
Regional and Country-Level Analysis
North America
North America held 42% of global revenue in 2025, equal to USD 0.72 billion. The United States represented 36% of the global market, or USD 0.62 billion, supported by a large diabetes population, widespread smartphone access, CGM integration and strong digital-health purchasing by employers, health plans and providers. Emerging Medicare pathways create an additional route for validated applications, but vendors must meet credentialing, interoperability and outcome-reporting requirements.
Canada accounted for 4%, valued at USD 0.07 billion, with adoption across consumer self-management, provincial care initiatives and private benefits. Mexico and the remaining regional market supplied close to 2%. North American competition is intense, and customer acquisition can be expensive. Enterprise distribution, device partnerships and reimbursement access therefore have more strategic value than app-store visibility alone.
Europe
Europe generated 27% of 2025 revenue, equal to USD 0.46 billion. Germany represented 7% globally, or USD 0.12 billion, supported by structured digital-health pathways and strong diabetes-device adoption. The United Kingdom held 5%, valued at USD 0.09 billion, while France accounted for 4%, or USD 0.07 billion. Italy, Spain, the Nordic markets and the rest of Europe contributed the regional balance.
European expansion requires country-specific regulatory, language and reimbursement strategies. Integration with national healthcare infrastructure can create scale, but procurement and evidence requirements vary. Platforms also need privacy-by-design controls and clear distinctions between medical-device software and general self-management functions.
Asia-Pacific
Asia-Pacific accounted for 24% of 2025 revenue, equal to USD 0.41 billion, and is forecast to grow fastest through 2035. China represented 7% of global sales, or USD 0.12 billion, due to its large diabetes population and mobile-health ecosystem. Japan held 5%, valued at USD 0.09 billion, where aging, strong device adoption and established healthcare access support connected diabetes tools. India generated 4%, or USD 0.07 billion, with opportunity tied to smartphone-based care, multilingual education and lower-cost programs.
Commercial models must reflect regional purchasing power. Direct subscriptions may work in affluent urban segments, while employer, provider, pharmaceutical and insurer partnerships can extend reach elsewhere. Localization requires more than translation; meal databases, care pathways, medication names and coaching must reflect local practice.
Latin America
Latin America held 4% of global revenue in 2025, valued at USD 0.07 billion. Brazil is the largest national market, followed by Mexico, which is included in North America in this report. Smartphone access creates a strong delivery channel, but reimbursement and specialist availability vary. Freemium models, pharmacy partnerships and provider-led programs can improve access, provided applications function reliably on lower-cost devices and intermittent connections.
Middle East and Africa
The Middle East and Africa represented 3% of 2025 revenue, equal to USD 0.05 billion. Gulf countries lead paid adoption through high smartphone use and investment in connected healthcare. South Africa is a key sub-Saharan market, while wider regional growth depends on affordable programs, language support and integration with primary-care or public-health initiatives. Applications designed for low-bandwidth use and shared-care models have an advantage where specialist diabetes services are limited.
Competitive Landscape
Competition includes independent digital-health companies, glucose-monitoring manufacturers, chronic-care platforms and regional application providers. Glooko differentiates through device-neutral data integration and clinical workflows. Welldoc emphasizes AI-powered cardiometabolic care and regulated software capabilities. Roche’s mySugr connects self-management with the Accu-Chek ecosystem, while Abbott and Dexcom use applications to extend the value of glucose-sensing platforms.
Glooko, Inc.
Glooko provides diabetes data management for people with diabetes, clinicians, health systems and life-sciences organizations. Its platform connects with a broad range of glucose meters, CGMs, insulin pumps and activity devices, consolidating information into patient and clinician views. The company also supports EHR and API integration, remote monitoring and population-level workflows. EndoTool, offered through Monarch Medical Technologies, extends the wider company portfolio into inpatient insulin-dosing support.
Glooko’s competitive position is based on device neutrality and clinical workflow integration. In June 2026, it introduced an EHR integration that brings insulin-pump settings into clinical workflows, reducing manual retrieval. In September 2026, the company added GestationalCare, a module designed for diabetes during pregnancy. The expansion shows a strategy of building condition-specific workflows on top of a shared diabetes data platform.
Welldoc, Inc.
Welldoc operates an AI-powered platform for diabetes and broader cardiometabolic conditions, including obesity, hypertension and complex comorbidities. Its system combines connected-device data, personalized coaching, enterprise dashboards and EHR integration. The company states that its platform connects to more than 400 devices and data sources and is supported by multiple FDA clearances, patents and peer-reviewed publications.
Welldoc is positioning its technology for reimbursed and enterprise care. In April 2026, it announced access for Medicare beneficiaries through the CMS ACCESS Model and Medicare App Library. In June, it partnered with Senseonics to develop a next-generation application for the Eversense 365 CGM. In July, it began operating as a credentialed Medicare Part B supplier within ACCESS. These moves strengthen distribution beyond employer wellness and place greater emphasis on accountable chronic-care delivery.
DexCom, Inc.
Dexcom develops glucose biosensing systems supported by mobile applications and data-sharing services. Its application ecosystem includes Dexcom apps for diabetes management and Stelo for people not using insulin who want glucose and metabolic insights. App functions include real-time readings, trend information, alerts, reports and sharing with caregivers or clinicians, with features varying by product and jurisdiction.
In June 2026, Dexcom announced a redesigned Stelo application with pattern recognition, proactive AI coaching and personalized daily and weekly summaries. The company also announced its planned acquisition of Nutrisense to add dietitian access, nutrition education and behavior-change support. The strategy extends Dexcom from sensor visualization into a broader software-and-service relationship centered on metabolic health.
Roche Diabetes Care and mySugr
Roche Diabetes Care combines Accu-Chek glucose-management products with the mySugr application and Accu-Chek Care platform. mySugr supports glucose, meal, activity and medication records and connects with compatible devices. The clinical platform enables consent-based data sharing with healthcare professionals for review of patterns, reports and treatment discussions.
Roche is consolidating more of the Accu-Chek SmartGuide CGM experience into mySugr, including real-time data, alarms, patterns and predictive information in supported markets. The company is also managing portfolio transitions: the mySugr Pump Control function was retired on June 29, 2026, following discontinuation of the related Accu-Chek Insight pump hardware. The change illustrates the dependency of diabetes apps on supported hardware and the need for clear migration paths.
Recent Developments
- September 1, 2026: Glooko launched GestationalCare, expanding its ambulatory diabetes platform with workflows designed for diabetes management during pregnancy.
- July 8, 2026: Welldoc began operating under the CMS ACCESS Model as a credentialed Medicare Part B supplier, creating a reimbursement route for scalable digital-first chronic care.
- June 23, 2026: Dexcom announced pediatric clearance for Stelo and detailed the July rollout of a redesigned app featuring clearer glucose insights. The company also outlined international expansion plans.
- June 10, 2026: Senseonics and Welldoc announced a partnership to develop a next-generation application for the Eversense 365 continuous glucose monitoring system.
- June 5, 2026: Glooko introduced an integration that brings insulin-pump settings into electronic health record workflows, reducing reliance on separate portals and manual data transfer.
- May 27, 2026: Abbott secured CE Mark for Libre Duo and Libre Duo 10 Day, systems designed to measure glucose and ketones continuously. Their applications provide the interface for real-time readings and emerging ketone-risk visibility.
Strategic Takeaways
- Device connectivity is becoming market infrastructure. Platforms that reliably normalize data across multiple CGMs, meters, pumps and pens can win health-system contracts that closed ecosystems cannot serve alone.
- Predictive features require evidence proportional to their influence on treatment. Vendors should separate educational forecasts from dosing or diagnostic claims and build regulatory strategy into product design.
- Diabetes and weight management are converging around GLP-1 use, nutrition and metabolic monitoring. Unified cardiometabolic programs can raise contract value and reduce application fragmentation.
- Reimbursement creates scale but changes operating requirements. Credentialing, clinical oversight, documentation and outcome reporting become as important as software engagement.
- Pregnancy-specific diabetes management is a defensible specialization because it requires tighter targets, defined episode duration and close clinician-patient coordination.
- Hardware discontinuation can remove application functionality even when the software remains active. Vendors need transparent support periods, data-retention policies and migration plans.
- Asia-Pacific growth will favor localized, Android-first platforms with regional food databases, language support and commercial models designed for varied healthcare coverage.
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global diabetes management apps market report delivers a detailed analysis with 70 key tables, more than 58 visually impactful figures, and 292 pages of expert insights, providing a complete view of the market landscape.
Target Audience
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.

























































